We recently published a list of 15 Best Fast Growth Stocks To Buy Right Now. In this article, we are going to take a look at ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...

The heavy selling pressure might have exhausted for Sarepta Therapeutics (SRPT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic ...

Solid said that the first patients to receive its Duchenne gene therapy all produced high levels of the target protein, an ...

TD Cowen analyst Ritu Baral reiterated a Buy rating on Vera Therapeutics (VERA – Research Report) yesterday and set a price target of $60.00.

William Blair analyst Sami Corwin maintained a Hold rating on BioMarin Pharmaceutical (BMRN – Research Report) today. The company’s shares ...

Solid Biosciences’ gene therapy uses a shortened version of the dystrophin protein, which is engineered to mimic the key ...

The Duchenne muscular dystrophy (DMD) market is projected to grow from $2.3 billion in 2023 to $5.2 billion in 2033 across seven major markets, driven by recent approvals of novel therapies, says ...